Reneo Pharmaceuticals Alpha and Beta Analysis
| RPHMDelisted Stock | USD 18.20 1.40 8.33% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Reneo Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Reneo Pharmaceuticals over a specified time horizon. Remember, high Reneo Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Reneo Pharmaceuticals' market risk premium analysis include:
Beta 0.62 | Alpha 0.25 | Risk 3.79 | Sharpe Ratio 0.23 | Expected Return 0.86 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Reneo |
Reneo Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Reneo Pharmaceuticals market risk premium is the additional return an investor will receive from holding Reneo Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Reneo Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Reneo Pharmaceuticals' performance over market.| α | 0.25 | β | 0.62 |
Reneo Pharmaceuticals Fundamentals Vs Peers
Comparing Reneo Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Reneo Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Reneo Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Reneo Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Reneo Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Reneo Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Reneo Pharmaceuticals to competition |
| Fundamentals | Reneo Pharmaceuticals | Peer Average |
| Return On Equity | -0.54 | -0.31 |
| Return On Asset | -0.34 | -0.14 |
| Current Valuation | (15.01 M) | 16.62 B |
| Shares Outstanding | 3.34 M | 571.82 M |
| Shares Owned By Insiders | 5.19 % | 10.09 % |
| Shares Owned By Institutions | 87.75 % | 39.21 % |
| Number Of Shares Shorted | 3.4 M | 4.71 M |
Reneo Pharmaceuticals Opportunities
Reneo Pharmaceuticals Return and Market Media
The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | RPHM Stock Earnings Reneo Pharmaceuticals Misses EPS for Q2 2024 | 08/13/2024 |
2 | Acquisition by Leonard Braden Michael of 100487 shares of Reneo Pharmaceuticals at 1.4132 subject to Rule 16b-3 | 08/14/2024 |
3 | RPHM Stock Alert Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to Shareholders | 09/03/2024 |
4 | Acquisition by Leonard Braden Michael of 172747 shares of Reneo Pharmaceuticals at 1.3712 subject to Rule 16b-3 | 09/16/2024 |
5 | Reneo Pharmaceuticals executive buys over 76k in company stock | 09/19/2024 |
6 | Acquisition by Leonard Braden Michael of 68746 shares of Reneo Pharmaceuticals at 1.4964 subject to Rule 16b-3 | 09/25/2024 |
7 | Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure | 10/03/2024 |
8 | OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of 65 Million | 10/04/2024 |
About Reneo Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Reneo or other delisted stocks. Alpha measures the amount that position in Reneo Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Reneo Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Reneo Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Reneo Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Reneo Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Reneo Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Reneo Pharmaceuticals' management manipulating its earnings.
| 25th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 25th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Reneo Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in Reneo Stock
If you are still planning to invest in Reneo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reneo Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |